Menu
Diffusion Pharmaceuticals (DFFN), a biopharmaceutical company announced that its Board of Directors has authorized a thorough review and evaluation of a range of potential strategic opportunities in the interest of enhancing stockholder value.
Update(s):
December 16, 2022: Diffusion (DFFN) has agreed that in the event it has not completed a transaction resulting from its ongoing strategic review process by July 1, 2023, the company will promptly appoint an individual designated by LifeSci Special Opportunities to the Board, subject to certain conditions.